2024-03-15 05:23:07 ET
Autolus Therapeutics plc (AUTL)
Q4 2023 Earnings Conference Call
March 14, 2024, 08:30 AM ET
Company Participants
Olivia Manser - Investor Relations
Christian Itin - Chief Executive Officer
Rob Dolski - Chief Financial Officer
Conference Call Participants
James Shin - Deutsche Bank
Gil Blum - Needham & Company
Eric Yeung - William Blair
Yanan Zhu - Wells Fargo
Jacob Mekhael - KBC Securities
Presentation
Operator
Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics' Call to discuss the Full Year 2023 Financial Results and business Updates. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Olivia Manser. Please go ahead.
Olivia Manser
Thanks, Michelle. Good morning or good afternoon, everyone. Thanks for joining us on today's call.
With me are Dr. Christian Itin, our Chief Executive Officer; and Rob Dolski, our Chief Financial Officer.
So, on Slide 2, before we begin, I'd just like to remind you that during today's call we will make statements related to our business that are forward-looking under federal securities laws and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding the status of clinical trials and development and for regulatory timelines for our product candidates and our expectations regarding our cash runway.
These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements. For a discussion of the material risks and uncertainties that could affect our actual results, please refer to the risks identified in today's press release and our SEC filings, both available on the Investors section of our website....
Read the full article on Seeking Alpha
For further details see:
Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript